Key Points
- Boston Scientific director Edward Ludwig bought 3,580 shares at an average price of $56.68, a purchase worth about $202,914 and boosting his ownership by 16.44%.
- The company also announced a $5 billion stock buyback program, authorizing repurchases of up to 6.4% of outstanding shares, which may signal management believes the stock is undervalued.
- Boston Scientific recently beat quarterly earnings and revenue estimates, with EPS of $0.80 on revenue of $5.20 billion, and it raised guidance for Q2 2026 and full-year 2026.
Boston Scientific Corporation (NYSE:BSX - Get Free Report) Director Cheryl Pegus acquired 1,770 shares of the business's stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director directly owned 1,770 shares of the company's stock, valued at $99,987.30. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.
Boston Scientific Stock Up 0.7%
Shares of BSX opened at $57.08 on Friday. The company has a 50-day simple moving average of $62.21 and a 200-day simple moving average of $80.40. The firm has a market capitalization of $84.84 billion, a P/E ratio of 23.88, a P/E/G ratio of 1.04 and a beta of 0.62. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52 week low of $52.52 and a 52 week high of $109.50.
Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the prior year, the business earned $0.75 earnings per share. The firm's revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 3.38 earnings per share for the current year.
Boston Scientific announced that its board has authorized a share buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's board of directors believes its shares are undervalued.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on BSX. Stifel Nicolaus decreased their price target on shares of Boston Scientific from $90.00 to $85.00 and set a "buy" rating on the stock in a research note on Tuesday, April 21st. Barclays decreased their price target on shares of Boston Scientific from $124.00 to $96.00 and set an "overweight" rating on the stock in a research note on Thursday, April 23rd. Wall Street Zen downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Saturday, March 28th. Weiss Ratings downgraded shares of Boston Scientific from a "hold (c)" rating to a "hold (c-)" rating in a research note on Wednesday, May 13th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Boston Scientific from $135.00 to $100.00 and set an "overweight" rating on the stock in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $92.71.
View Our Latest Report on BSX
Boston Scientific News Roundup
Here are the key news stories impacting Boston Scientific this week:
- Positive Sentiment: Multiple Boston Scientific directors bought shares this week, including David C. Habiger, Edward J. Ludwig, and Cheryl Pegus. Heavy insider buying is often seen as a vote of confidence from management and can boost investor sentiment. Article Title
- Positive Sentiment: Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter, with the FRACTURE trial meeting all primary safety and effectiveness endpoints. That strengthens the case for future regulatory approval and supports the company’s growth story. Article Title
- Neutral Sentiment: Baird kept an Outperform rating on BSX but trimmed its price target to $75 from $78, suggesting Wall Street still likes the name even as expectations are being adjusted. Article Title
- Negative Sentiment: Some recent commentary said Boston Scientific fell due to weak results, which may be weighing on sentiment and reminding investors that the stock has faced pressure despite longer-term growth prospects. Article Title
Institutional Investors Weigh In On Boston Scientific
Several institutional investors and hedge funds have recently made changes to their positions in BSX. Brighton Jones LLC boosted its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. FWL Investment Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth about $26,000. Main Street Financial Solutions LLC lifted its position in Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider's stock worth $812,000 after buying an additional 1,971 shares in the last quarter. Ieq Capital LLC lifted its position in Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider's stock worth $13,275,000 after buying an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC lifted its position in Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider's stock worth $763,000 after buying an additional 2,556 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.
Boston Scientific Company Profile
(
Get Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
